Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
暂无分享,去创建一个
A. Papaefthymiou | D. Giakoustidis | V. Papadopoulos | A. Giakoustidis | A. Koffas | C. Toumpanakis | P. Bangeas | Apostolis Papaefthymiou
[1] C. Fiorino,et al. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features , 2022, European Radiology.
[2] D. Bailey,et al. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score , 2022, British Journal of Cancer.
[3] S. Busoni,et al. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade , 2022, La radiologia medica.
[4] N. Suzuki,et al. State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors , 2022, Current Treatment Options in Oncology.
[5] V. Prasad,et al. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease , 2022, Journal of neuroendocrinology.
[6] M. Papotti,et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.
[7] M. Caplin,et al. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors , 2022, Clinical nuclear medicine.
[8] Clara C. Chen,et al. Parathyroid Imaging: Past, Present, and Future , 2022, Frontiers in Endocrinology.
[9] M. Weickert,et al. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours , 2021, Frontiers in Endocrinology.
[10] G. Cassese,et al. Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs) , 2021, Diagnostics.
[11] D. Metz,et al. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors , 2021, JAMA network open.
[12] Tsuyoshi Hayashi,et al. Role of Endoscopic Ultrasound in the Diagnosis of Pancreatic Neuroendocrine Neoplasms , 2020, Diagnostics.
[13] A. Koffas,et al. Managing carcinoid heart disease in patients with neuroendocrine tumours. , 2020, Annales d'endocrinologie.
[14] Mohid S. Khan,et al. Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours. , 2020, The Journal of clinical endocrinology and metabolism.
[15] D. Cuthbertson,et al. The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs). , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[16] K. Öberg. Molecular Genomic Blood Biomarkers for Neuroendocrine Tumors: The Long and Winding Road from Berzelius and Bence Jones to a Neuroendocrine Destination , 2020, Neuroendocrinology.
[17] M. Falconi,et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Califano,et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Jeffrey E. Lee,et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.
[20] G. Kaltsas,et al. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms , 2020, Endocrine reviews.
[21] S. Severi,et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[22] L. Eusebi,et al. Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors , 2019, Endoscopy International Open.
[23] I. Modlin,et al. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis , 2019, Neuroendocrinology.
[24] G. Vitale,et al. MANAGEMENT OF ENDOCRINE DISEASE: Precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives. , 2019, European journal of endocrinology.
[25] L. Hofland,et al. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives , 2018, Drugs.
[26] I. Drozdov,et al. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. , 2018, Endocrinology and metabolism clinics of North America.
[27] R. Jensen,et al. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies , 2018, Expert review of anticancer therapy.
[28] A. Kambadakone,et al. MR Imaging of Pancreatic Neuroendocrine Tumors. , 2018, Magnetic resonance imaging clinics of North America.
[29] A. Cooperman,et al. Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat? , 2018, The Surgical clinics of North America.
[30] S. Lo,et al. The role of pre‐operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? , 2018, Journal of surgical oncology.
[31] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[32] A. Gangi,et al. Multifocality in Small Bowel Neuroendocrine Tumors , 2018, Journal of Gastrointestinal Surgery.
[33] N. Kumta,et al. Diagnosis and Management of Rectal Neuroendocrine Tumors , 2017, Clinical endoscopy.
[34] Shouhao Zhou,et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.
[35] R. Hruban,et al. Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification , 2017, AJSP: Reviews and Reports.
[36] E. Nakakura,et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society , 2017, Pancreas.
[37] R. Lloyd,et al. WHO classification of tumours of endocrine organs , 2017 .
[38] V. Mazzaferro,et al. The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors. , 2017, Journal of gastrointestinal and liver diseases : JGLD.
[39] V. Ostojić,et al. Incidence of diabetic ketosis and ketoacidosis in Caucasian adults with type 2 diabetes mellitus: a population-based study , 2017 .
[40] R. Jensen,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers , 2017, Neuroendocrinology.
[41] S. Fanti,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging , 2017, Neuroendocrinology.
[42] S. Kim,et al. Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors? , 2017, World journal of gastroenterology.
[43] R. Jensen,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification , 2017, Neuroendocrinology.
[44] M. Pavel,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors , 2017, Neuroendocrinology.
[45] S. Michopoulou,et al. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors , 2017, The Journal of Nuclear Medicine.
[46] Denis A. Cortese,et al. A Five-Year Experience , 2017 .
[47] G. Vitale,et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors , 2017, Endocrine.
[48] Laura H. Tang,et al. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas , 2016, The American journal of surgical pathology.
[49] A. Dohan,et al. Neuroendocrine tumors of the small bowel: evaluation with MR-enterography. , 2016, Clinical imaging.
[50] A. Larghi,et al. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography , 2016, Pancreas.
[51] Raju Sharma,et al. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. , 2016, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[52] Y. Oda,et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors , 2016, Scandinavian journal of gastroenterology.
[53] E. Krenning,et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.
[54] R. Kianmanesh,et al. ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update , 2016, Neuroendocrinology.
[55] R. Jensen,et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.
[56] R. Main. Long-term Evaluation , 2016 .
[57] C. Rottenburger,et al. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. , 2016, Best practice & research. Clinical endocrinology & metabolism.
[58] K. Nackaerts,et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours , 2016, European Radiology.
[59] I. Modlin,et al. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. , 2015, The Journal of clinical endocrinology and metabolism.
[60] J. Mortensen,et al. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients , 2015, The Journal of Nuclear Medicine.
[61] K. Delman,et al. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach , 2015, Annals of Surgical Oncology.
[62] M. Ruiz,et al. Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours , 2015, Nuclear medicine communications.
[63] U. Knigge,et al. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. , 2014, Future oncology.
[64] I. Adalet,et al. Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors? , 2014, The Journal of Nuclear Medicine.
[65] M. Cuggia,et al. High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.
[66] G. Corradi,et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial , 2014, The Journal of Nuclear Medicine.
[67] M. Büchler,et al. A Systematic Review of Localization, Surgical Treatment Options, and Outcome of Insulinoma , 2014, Pancreas.
[68] A. Faggiano,et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. , 2014, Endocrine-related cancer.
[69] B. Ge,et al. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis , 2014, Acta radiologica.
[70] G. Rindi,et al. The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: a Critical Appraisal four years after Its Introduction , 2014, Endocrine Pathology.
[71] G. Antoni,et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. , 2014, The Journal of clinical endocrinology and metabolism.
[72] A. Larghi,et al. Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy? , 2014, Gland surgery.
[73] T. Ohtsuka,et al. Expression of Glucagon-Like Peptide 1 Receptor and its Effects on Biologic Behavior in Pancreatic Neuroendocrine Tumors , 2014, Pancreas.
[74] C. Sempoux,et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound‐guided fine needle aspiration: high reproducibility and inter‐observer agreement of the Ki‐67 labelling index , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.
[75] A. Scarpa,et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. , 2014, Surgery.
[76] J. Bomanji,et al. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. , 2014, PET clinics.
[77] Xubao Liu,et al. Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. , 2014, The Journal of surgical research.
[78] C. Stanley,et al. The surgical management of insulinomas in children. , 2013, Journal of pediatric surgery.
[79] Yulian Wu,et al. Surgical treatment of pancreatic islet cell tumor: report of 44 cases. , 2013, Hepato-gastroenterology.
[80] A. Bellizzi. Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms: A Clinically Significant Application of Diagnostic Immunohistochemistry , 2013, Advances in anatomic pathology.
[81] F. Tubach,et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. , 2013, Radiology.
[82] L. Breimer,et al. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[83] L. Mishra,et al. Technologies for deriving primary tumor cells for use in personalized cancer therapy. , 2013, Trends in biotechnology.
[84] R. Jensen,et al. Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A Prospective Study , 2013, Medicine.
[85] Mohid S. Khan,et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] H. Sorbye,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] Y. Menda,et al. The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.
[88] U. Knigge,et al. Surgery for GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.
[89] M. Falconi,et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. , 2012, Gastrointestinal endoscopy.
[90] A. Miyauchi,et al. Delay in the diagnosis of multiple endocrine neoplasia type 1: typical symptoms are frequently overlooked. , 2012, Endocrine journal.
[91] A. Scarpa,et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. , 2012, Journal of the National Cancer Institute.
[92] I. Shimon,et al. The Role of Cell Lines in the Study of Neuroendocrine Tumors , 2012, Neuroendocrinology.
[93] P. Castaldi,et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis , 2012, Endocrine.
[94] P. Ameri,et al. Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New? , 2012, Neuroendocrinology.
[95] H. Sasano,et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.
[96] M. Papotti,et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms , 2011, Neuroendocrinology.
[97] T. Gress,et al. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.
[98] R. Jensen,et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes , 2011, Neuroendocrinology.
[99] P. Cumming,et al. Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.
[100] H. Amthauer,et al. 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.
[101] M. Caplin,et al. Risk factors for the development and progression of carcinoid heart disease. , 2011, The American journal of cardiology.
[102] J. Tokar,et al. Small Bowel Cancers Diagnosed by Device-Assisted Enteroscopy at a U.S. Referral Center: A Five-Year Experience , 2011, Digestive Diseases and Sciences.
[103] Ben Lawrence,et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.
[104] Mohid S. Khan,et al. Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors , 2011, Clinical Cancer Research.
[105] D. Breen,et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.
[106] A. Goules,et al. Prognostic Factors and Survival , 2011 .
[107] P. Rajiah,et al. Computed tomography of cardiac and pericardiac masses. , 2011, Journal of cardiovascular computed tomography.
[108] P. Veit-Haibach,et al. Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component , 2011, European Radiology.
[109] A. Bockisch,et al. The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors , 2010, Annals of surgery.
[110] D. Visvikis,et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients , 2010, Nuclear medicine communications.
[111] Zhi-gang Yang,et al. Accuracy and reproducibility of assessing right ventricular function with 64-section multi-detector row CT: comparison with magnetic resonance imaging. , 2010, International journal of cardiology.
[112] A. Hackshaw,et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours , 2010, British Journal of Cancer.
[113] F. Pilleul,et al. Value of CT enteroclysis in suspected small-bowel carcinoid tumors. , 2010, AJR. American journal of roentgenology.
[114] Ka Kit Wong,et al. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. , 2010, Academic radiology.
[115] E. Nakakura,et al. Identification of Unknown Primary Tumors in Patients With Neuroendocrine Liver Metastases , 2010, Archives of surgery.
[116] A. Kjaer,et al. F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .
[117] 三井 啓吾,et al. Role of double-balloon endoscopy in the diagnosis of small-bowel tumors : the first Japanese multicenter study , 2010 .
[118] F. Greenway,et al. An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .
[119] F. Forrer,et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. , 2009, The Journal of clinical endocrinology and metabolism.
[120] Shinji Tanaka,et al. Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. , 2009, Gastrointestinal endoscopy.
[121] R. Bale,et al. Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.
[122] P. Cryer,et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. , 2009, The Journal of clinical endocrinology and metabolism.
[123] M. Vatn,et al. Small intestinal neuroendocrine tumors: Prognostic factors and survival , 2009, Scandinavian journal of gastroenterology.
[124] A. Groves,et al. A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.
[125] R. Bale,et al. Tyr 3 -Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009 .
[126] P. Malfertheiner,et al. Detection of Neuroendocrine Tumors of the Small Bowel by Double Balloon Enteroscopy , 2009, Digestive Diseases and Sciences.
[127] M. Caplin,et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. , 2008, The American journal of cardiology.
[128] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[129] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] P. Erba,et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[131] F. Schmidt. Meta-Analysis , 2008 .
[132] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[133] F. D. De Braud,et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. , 2007, Endocrine-related cancer.
[134] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.
[135] C. Nanni,et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[136] J. Manson,et al. Prospective Study of , 2007 .
[137] J. Saurin,et al. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. , 2006, Radiology.
[138] R. Jensen,et al. Serum Gastrin in Zollinger-Ellison Syndrome: I. Prospective Study of Fasting Serum Gastrin in 309 Patients From the National Institutes of Health and Comparison With 2229 Cases From the Literature , 2006, Medicine.
[139] E. D. de Vries,et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.
[140] A. Hubalewska-Dydejczyk,et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[141] Joel G Fletcher,et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.
[142] H. Lochs,et al. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. , 2006, Gastrointestinal endoscopy.
[143] B. Weinhold. Epigenetics: The Science of Change , 2006, Virchows Archiv.
[144] R. Jensen,et al. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. , 2005, Best practice & research. Clinical gastroenterology.
[145] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[146] T. de Baère,et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] A. Ferrari,et al. EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. , 2004, Gastrointestinal endoscopy.
[148] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[149] R. Wahl,et al. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS , 2004, Abdominal Imaging.
[150] H. Gouya,et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. , 2003, AJR. American journal of roentgenology.
[151] J. Fletcher,et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. , 2003, AJR. American journal of roentgenology.
[152] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[153] Uwe Haberkorn,et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[154] R. Lloyd. Practical markers used in the diagnosis of neuroendocrine tumors , 2003, Endocrine pathology.
[155] S. Gabriel,et al. Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.
[156] G. delle Fave,et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid , 2001, European journal of gastroenterology & hepatology.
[157] J. Norton,et al. Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. , 2001, Archives of surgery.
[158] D. Jonkers,et al. Serum chromogranin A as a screening test for gastric enterochromaffin‐like cell hyperplasia during acid‐suppressive therapy , 2001, European journal of clinical investigation.
[159] M. Falconi,et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization , 2001, European Radiology.
[160] E. D. de Vries,et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. , 2000, Clinical chemistry.
[161] Michelle A. Anderson,et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.
[162] T. Ichikawa,et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. , 2000, Radiology.
[163] B. Wiedenmann,et al. Endoscopic Ultrasonography of Neuroendocrine Tumours , 2000, Digestion.
[164] C. Angelis,et al. Endosonography in decision making and management of gastrointestinal endocrine tumors. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.
[165] J. Doppman,et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[166] T. Ichikawa,et al. Neuroendocrine Tumor of the Pancreas : Biphasic CT versus MR Imaging in Tumor Detection , 1999 .
[167] D. Huglo,et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. , 1998, Surgery.
[168] S. Fanti,et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours , 1998, European Journal of Nuclear Medicine.
[169] J. Mcnamara,et al. Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. , 1998, American journal of surgery.
[170] L. Holmberg,et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[171] H. Buhr,et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. , 1996, Gut.
[172] Y. Chapuis,et al. Endoscopic Ultrasonography for the Preoperative Localization of Insulinomas , 1996, Pancreas.
[173] D. Metz,et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. , 1995, Gastroenterology.
[174] P. Ruszniewski,et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. , 1995, Surgery.
[175] B. Wiedenmann,et al. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. , 1994, Gut.
[176] O. Luinetti,et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. , 1993, Gastroenterology.
[177] C. Lightdale,et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.
[178] W. Lees,et al. Endoscopic ultrasound for localisation of islet cell tumours. , 1992, Gut.
[179] P. E. Smith,et al. Orbital pseudotumour secondary to giant cell arteritis: an unreported condition. , 1990, BMJ.
[180] U. Hellman,et al. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. , 1990, Acta endocrinologica.
[181] D. O'Connor,et al. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. , 1989, Clinical chemistry.
[182] L. Deftos,et al. Hormone-negative, chromogranin A-positive endocrine tumors. , 1989, The New England journal of medicine.
[183] P. Cisek,et al. Catechol estrogen adducts. , 1988, Journal of steroid biochemistry.
[184] K. Johnson. An Update. , 1984, Journal of food protection.
[185] J. Glass,et al. Biochemical markers. , 1981, Science.
[186] J. Galambos,et al. Diagnosis of gastrinoma by the secretin suppression test. , 1976, Surgery, gynecology & obstetrics.
[187] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.
[188] N. Levine. THE BIOLOGICAL APPROACH , 1950 .